The Pandemic Is Not Associated with Endophthalmitis Decrease after Anti–Vascular Endothelial Growth Factor Injections
- 15 January 2022
- journal article
- editorial
- Published by Elsevier BV in Ophthalmology
- Vol. 129 (6), 719-721
- https://doi.org/10.1016/j.ophtha.2022.01.009
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Ophthalmology and COVID-19: The Impact of the Pandemic on Patient Care and Outcomes: An IRIS® Registry StudyOphthalmology, 2021
- Trends in Endophthalmitis Associated With Intravitreal Injection of Anti-VEGF Agentsat a Tertiary Referral CenterOphthalmic Surgery, Lasers and Imaging Retina, 2021
- The Influence of Universal Face Mask Use on Endophthalmitis Risk after Intravitreal Anti–Vascular Endothelial Growth Factor InjectionsOphthalmology, 2021
- ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTIONS DURING THE COVID-19 PANDEMIC WITH IMPLEMENTATION OF UNIVERSAL MASKINGRetina, 2021
- The Impact of Physician Face Mask Use on Endophthalmitis After Intravitreal Anti–Vascular Endothelial Growth Factor InjectionsAmerican Journal of Ophthalmology, 2020
- The 2016 American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight) DatabaseOphthalmology, 2018
- Meta-Analysis of Infectious Endophthalmitis After Intravitreal Injection of Anti-Vascular Endothelial Growth Factor AgentsOphthalmic Surgery, Lasers and Imaging Retina, 2014